复方樟柳碱注射液治疗前部缺血性视神经病变的药品综合评价  

Comprehensive Evaluation on Compound Anisodine Hydrobromide Injection in the Treatment of Anterior Ischemic Optic Neuropathy

作　　者：冯英楠 邢晓璇[1] 李晓曦 庄伟[1] 王之舟[1] 王可[1] 张兰[1] 董宪喆 FENG Yingnan;XING Xiaoxuan;LI Xiaoxi;ZHUANG Wei;WANG Zhizhou;WANG Ke;ZHANGLan;DONG Xianzhe(Dept.of Pharmacy,Xuanwu Hospital of Capital Medical University,National Clinical Research Center for Geriatric Disease,Beijing 100053,China)

机构地区：[1]首都医科大学宣武医院药学部,国家老年疾病临床医学研究中心,北京100053

出　　处：《中国医院用药评价与分析》2024年第9期1109-1112,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：首都卫生发展科研专项(No.首发2024-2-2019);北京市医院管理中心“登峰”人才培养计划项目(No.DFL20190803);中国科学技术协会科技智库青年人才计划项目(No.20220615ZZ07110070)。

摘　　要：目的:对复方樟柳碱注射液治疗前部缺血性视神经病变进行药品综合评价,为临床用药决策提供证据支持。方法:检索PubMed、中国知网等中英文数据库及药品生产企业和市场情况等,获取相关数据。从有效性、安全性、经济性、创新性、适宜性和可及性6个维度对复方樟柳碱注射液治疗前部缺血性视神经病变进行综合评价。结果:检索到915篇文献,最终共纳入14项随机对照试验研究。有效性方面,与对照药物相比,复方樟柳碱注射液治疗有效率显著升高,差异有统计学意义(P<0.05);安全性方面,复方樟柳碱注射液与对照药物的不良反应发生率比较,差异无统计学意义(P>0.05);经济性方面,与对照药物相比,复方樟柳碱注射液日治疗费用为17.97元,费用较低。复方樟柳碱注射液为眼科国家三类新药,使用操作无特殊要求,患者可负担性较高。结论:复方樟柳碱注射液治疗前部缺血性视神经病变的临床有效率较高,不良反应发生率较低,日治疗费用有一定优势。医护人员操作方便,覆盖地域范围广,可获得性良好。OBJECTIVE:To conduct a comprehensive drug evaluation on compound anisodine hydrobromide injection in the treatment of anterior ischaemic optic neuropathy,so as to provide evidence support for clinical medication decisions.METHODS:Related data were obtained by searching Chinese and English databases such as PubMed and CNKI,as well as drug manufacturers and market conditions.Comprehensive evaluation on compound anisodine hydrobromide injection in the treatment of anterior ischaemic optic neuropathy was conducted from six dimensions:effectiveness,safety,economical efficiency,innovativeness,appropriateness and accessibility.RESULTS:A total of 14 randomized controlled trials from 915 retrieved papers were finally enrolled.In terms of effectiveness,compared with the control drug,the therapeutic effective rate of compound anisodine hydrobromide injection was significantly higher,with statistically significant difference(P<0.05).In terms of safety,the difference in incidences of adverse drug reactions between compound anisodine hydrobromide injection and the control drug was not statistically significant(P>0.05).In terms of economical efficiency,compared with the control drug,the daily therapeutic cost of compound anisodine hydrobromide injection was 17.97 RMB,the cost was lower.Compound anisodine hydrobromide injection was national classⅢnew drugs,with no special requirements for application and high affordability.CONCLUSIONS:Compound anisodine hydrobromide injection has high clinical effective rate in the treatment of anterior ischaemic optic neuropathy,with low incidence of adverse drug reactions and a certain advantage in daily treatment cost.It is convenient for medical staffs to operate,covers a wide geographic area,and has good accessibility.

关 键 词：复方樟柳碱注射液 前部缺血性视神经病变 药品综合评价 

分 类 号：R988.1[医药卫生—药品]